Alvimedica

Alvimedica is a Turkish medical-device company established in 2007 by Turkish businessman İshak Alaton. The company develops and manufactures products for interventional cardiology, with a portfolio associated with coronary stents, balloon catheters, diagnostic catheters and guiding catheters. Its customers are primarily hospitals, catheterization laboratories, physicians and other healthcare institutions rather than general consumers. The company’s headquarters are located in a 5,500-square-metre facility in the free-trade zone at Catalca in Istanbul. Its manufacturing operation includes a 700-square-metre Good Manufacturing Practice-compliant area used for the main assembly of catheter and stent systems. Public reference material describes the site as having one of Europe’s larger Class 10,000 cleanrooms, reflecting the controlled-environment requirements of implantable and catheter-based medical devices. Alvimedica’s best-known disclosed development is Coracto, a rapamycin-eluting coronary stent using a bioabsorbable polymer. The product was described as the first drug-eluting stent developed and manufactured in Turkey. Preclinical and clinical work associated with Coracto took place around 2009 and 2010. Reported animal research compared endothelial coverage and inflammatory responses for Coracto with sirolimus-eluting, everolimus-eluting and bare-metal stents in a rabbit iliac model. The cited study was exploratory and was not statistically powered to establish definitive significance. Beyond coronary products, the company has reported work on renal and cranial intravascular stents, as well as biodegradable stent technologies intended to dissolve inside the vessel after serving their therapeutic purpose. Its development model has included collaborations with Turkish universities such as Boğaziçi University, Istanbul University, Sabancı University, Bilkent University, Yıldız Technical University and Yeditepe University, together with international academic and clinical organizations including Drexel University, the Medical University of Vienna, CVPath and the Main-Taunus-Private Clinic. Alvimedica has also participated in professional education and healthcare-access initiatives. In partnership with the Turkish Society of Cardiology, it helped establish Turkey’s first cardiology simulation center. Through cooperation with the Stent for Life initiative, the program supported training for Turkish cardiologists and promoted faster diagnosis and treatment of acute myocardial infarction. In 2014–2015, the company sponsored a team competing in the Volvo Ocean Race, giving the medical-device brand a public-facing international sponsorship outside its core healthcare market. The company expanded through acquisitions during its early development. It purchased Nemed in 2007 and acquired the United States-based catheter manufacturer In-Vivo in 2009. In-Vivo produced angioplasty and angiography catheters and was described as a supplier to Abbott Laboratories. Available reference material does not establish Alvimedica’s current ownership, financial performance, executive roster, precise sales footprint or present regulatory status in individual markets. Those details are therefore not stated.

Alvimedica was founded in Turkey in 2007 by İshak Alaton as a medical-device business focused on interventional cardiology. Its early activities combined product development with manufacturing infrastructure for catheter and stent systems. The company’s principal site was established in the Catalca free-trade zone of Istanbul, where a 5,500-square-metre headquarters and production facility included a 700-square-metre GMP-compliant assembly area. Public descriptions also identify a large Class 10,000 cleanroom designed for the controlled manufacture of medical devices. The company pursued early expansion through acquisitions. In 2007, its first reported investment was the purchase of Nemed. Two years later, Alvimedica acquired In-Vivo, a United States company making angioplasty and angiography catheters. In-Vivo was also described as one of Abbott Laboratories’ suppliers. These transactions broadened Alvimedica’s capabilities beyond a single domestic manufacturing base and supported its participation in the international catheter market. Coronary intervention became the company’s most visible technology area. Alvimedica developed Coracto, a rapamycin-eluting coronary stent with a bioabsorbable polymer. Public material characterizes Coracto as the first drug-eluting stent developed and manufactured in Turkey. Its associated Coracto SDS delivery system was examined in preclinical work reported at EuroPCR in 2009, while clinical and preclinical studies were conducted around 2010. Animal testing compared Coracto with sirolimus-eluting and everolimus-eluting stents and with a bare-metal control in a rabbit iliac model. The reported observations concerned endothelial coverage and inflammation; the study was not designed to provide definitive statistical proof. Alvimedica’s development plans also included renal and cranial intravascular stents and biodegradable stents intended to dissolve completely within the vessel. The company supported research and development through relationships with Turkish universities, including Boğaziçi University, Istanbul University, Sabancı University, Bilkent University, Yıldız Technical University and Yeditepe University. International collaborations mentioned in public references include Drexel University, the Medical University of Vienna, CVPath International Registry of Pathology, the Main-Taunus-Private Clinic and the Turkish American Scientists and Scholars Association. The company has participated in education and treatment-access programs as well as device manufacturing. Working with the Turkish Society of Cardiology, it helped establish Turkey’s first cardiology simulation center. Together with the Stent for Life initiative, the partnership provided training for Turkish cardiologists and promoted rapid recognition and treatment of heart attacks, with an objective of ensuring that patients receive appropriate intervention within an hour. Alvimedica also sponsored a Volvo Ocean Race team during the 2014–2015 edition of the global sailing event. Available reference material does not provide a sufficiently reliable account of later ownership, current leadership, financial results, detailed regulatory approvals, present distribution arrangements or the commercial status of every disclosed development program. Accordingly, the documented history is strongest for the company’s founding, manufacturing base, acquisitions, Coracto research, academic collaborations, professional training work and 2014–2015 sponsorship.

• 2014

  Volvo Ocean Race sponsorship begins

  [1]Alvimedicaen.wikipedia.org

  Alvimedica sponsored a team competing in the 2014–2015 Volvo Ocean Race.

• 2010

  Coracto studies conducted

  [1]Alvimedicaen.wikipedia.org

  Preclinical and clinical studies associated with the Coracto drug-eluting stent were conducted.

• 2009

  In-Vivo acquired

  [1]Alvimedicaen.wikipedia.org

  Alvimedica acquired the United States catheter manufacturer In-Vivo, expanding its angioplasty and angiography product capabilities.

• 2009

  Coracto research presented

  [1]Alvimedicaen.wikipedia.org

  Preclinical findings for the Coracto stent delivery system were presented at EuroPCR.

• 2007

  Company founded

  [1]Alvimedicaen.wikipedia.org

  Alvimedica was founded in Turkey by İshak Alaton as a medical-device company focused on interventional cardiology.

• 2007

  Nemed acquired

  [1]Alvimedicaen.wikipedia.org

  The company made its first reported investment by acquiring medical-device company Nemed.

Interventional cardiology and catheter-based cardiovascular medical devices

• Drug-eluting coronary stent

  Coracto

  Coracto is a coronary drug-eluting stent using rapamycin and a bioabsorbable polymer. Public reference material describes it as the first drug-eluting stent developed and manufactured in Turkey. Its associated research examined vascular healing, endothelial coverage and inflammation in preclinical models, with clinical and preclinical work reported around 2009 and 2010.

• Stent delivery system

  Coracto SDS

  Coracto SDS is the stent delivery system associated with the Coracto coronary stent. Research presented at EuroPCR evaluated the system and its stent in a rabbit iliac model, comparing results with sirolimus-eluting, everolimus-eluting and bare-metal stents. The available material does not establish its current commercial or regulatory status.

• Interventional cardiology device

  Coronary stents

  Alvimedica’s coronary-stent activities cover implantable devices used during catheter-based treatment of narrowed coronary arteries. The company’s disclosed work includes drug-eluting and potentially biodegradable stent technologies. Specific product availability, indications and approvals vary by jurisdiction and are not established by the supplied material.

• Catheter-based cardiovascular device

  Balloon catheters

  Balloon catheters are used in vascular intervention, including procedures that dilate or prepare a narrowed vessel before or alongside stent placement. They form part of Alvimedica’s professional interventional-cardiology portfolio. The supplied references do not identify individual models or launch dates.

• Diagnostic cardiovascular catheter

  Diagnostic catheters

  Diagnostic catheters are used to access blood vessels and support imaging or assessment during cardiovascular procedures. Alvimedica is identified as a manufacturer of diagnostic catheters, although the available references do not provide a complete model list, technical specifications or current market status.

• Interventional cardiovascular catheter

  Guiding catheters

  Guiding catheters provide vascular access and support the delivery of interventional devices during catheterization procedures. They are among the product categories publicly associated with Alvimedica. No specific product names, launch dates or jurisdictional approvals are established in the supplied material.

• Intravascular stent development program

  Renal and cranial intravascular stents

  Alvimedica has reported development projects involving stents for renal and cranial vascular applications. The references identify these as current or planned projects but do not provide sufficient information about clinical validation, regulatory approval, commercial launch or present availability.

• Resorbable vascular stent development program

  Biodegradable stents

  The company has also reported work on biodegradable stents designed to dissolve completely within the treated vessel. This technology represents a development direction rather than a product whose commercial status can be confirmed from the supplied references.

• 2014Volvo Ocean Race sponsorship

  International

  Alvimedica sponsored a team in the 2014–2015 Volvo Ocean Race, using an international sailing event as a brand-visibility platform beyond its specialist medical-device audience.

  Outcome. The sponsorship ran through the 2014–2015 race edition. No reliable performance or commercial-return data is provided in the supplied material.

  Source
• 2012Stent for Life cardiology training

  Turkey

  Alvimedica worked with the Stent for Life initiative and the Turkish Society of Cardiology on professional training intended to improve the early recognition of heart attacks and speed access to appropriate intervention.

  Outcome. The partnership included training for Turkish cardiologists and supported the establishment of a cardiology simulation center. The supplied sources do not quantify its clinical outcomes.

  Source

• 2009

  Acquisition of In-VivoM&A

  Background

  Alvimedica sought to expand its catheter portfolio and international manufacturing capabilities.

  Action taken

  It acquired In-Vivo, a United States manufacturer of angioplasty and angiography catheters.

  Aftermath

  In-Vivo was described as one of Abbott Laboratories’ suppliers. The supplied material does not document the acquisition price, integration plan or later performance.

  Source

• 2009

  Coracto development and evaluationProduct launch

  Background

  The company pursued a locally developed drug-eluting coronary stent using a bioabsorbable polymer.

  Action taken

  Alvimedica advanced Coracto and its stent delivery system into preclinical and clinical evaluation, with animal findings presented at EuroPCR.

  Aftermath

  The research reported comparative observations on endothelial coverage and inflammation, but the cited animal study was not powered for definitive statistical significance. Commercial launch and approval details are not established.

  Source

• 2007

  Acquisition of NemedM&A

  Background

  Alvimedica identified acquisitions as an early means of building its medical-device business.

  Action taken

  The company purchased Nemed, described in the reference material as a medical-device company.

  Aftermath

  The supplied sources do not provide transaction terms, integration details or subsequent operating results.

  Source

1. 1Alvimedicaen.wikipedia.org